Ali Jawad Alyasiri ✉
Department of Biology, College of Science, Almuthanna University, Iraq
Received: Sept 15, 2023/ Revised: Oct 24, 2023/Accepted: Oct 30, 2023
(✉) Corresponding Author: Ali Jawad Alyasiri
Abstract
Given the urgency of the ongoing COVID-19 pandemic, its complications and deaths, the discovery of new mutated strains and the potential for re-emergence of novel coronaviruses, the reuse of drugs such as ivermectin may deserve attention. This review article aims to discuss the potential mechanisms of action of ivermectin against SARS-CoV-2, and COVID-19 by summarizing the available literature since the onset of the disease. Ivermectin inhibits the replication of SARS-CoV-2 in vitro at concentrations not readily achievable with currently approved doses. There is limited evidence to support its clinical use in COVID-19 patients In this comprehensive systematic review, multiple studies have reported that ivermectin exhibits antiviral properties against a wide range of RNA viruses, including Zika, dengue, yellow fever, West Nile, Hendra, Newcastle, Venezuelan equine encephalitis, chikungunya, Semliki Forest, Sindbis, Avian influenza A, Porcine Reproductive and Respiratory Syndrome, Human immunodeficiency virus type 1, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Furthermore, some studies have indicated that ivermectin also shows antiviral effects against DNA viruses, such as Equine herpes type 1, BK polyomavirus, pseudorabies, porcine circovirus 2, and bovine herpesvirus 1. Ivermectin’s antiviral actions are attributed to its involvement in various biological mechanisms, suggesting its potential as a candidate for treating a wide array of viruses, including COVID-19, and other positive-sense single-stranded RNA viruses. This systematic review encompasses evidence dating back to 1970, underscoring ivermectin’s capacity to combat a diverse array of viral infections. The findings of this study suggest that ivermectin might serve as a valuable antiviral agent for viruses, especially those with positive-sense single-stranded RNA genomes. Notably, experimental studies have shown significant effectiveness when ivermectin is administered during the early stages of infection, which implies its potential in early treatment or prevention. However, it’s important to note that confirming these assertions requires human studies and clinical trials.
Keywords: SARS CoV2, COVID-19, Ivermectin, Treatment
References
European Medicines Agency (EMA), (2021). EMA advises against use of ivermectin for the prevention or treatment COVID-19 outside randomised clinical trials. European Medicines Agency. 2021.
Annie, F. H., Campbell, J., Searls, L., & Amos, J. (2022). The Effect of Ivermectin on Cases of COVID-19. Cardiovascular Revascularization Medicine, 44, 98–100.
https://doi.org/10.1016/j.carrev.2022.06.004
Bartoszko, J. J., Siemieniuk, R. A., Kum, E., Qasim, A., Zeraatkar, D., Martinez, J. P. D., Brignardello-Petersen, R. (2021). Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ, n949.
https://doi.org/10.1136/bmj.n949
Beard, E. L. (2001). The American Society of Health System Pharmacists. JONA’s Healthcare Law, Ethics, and Regulation, 3(3), 78–79.
https://doi.org/10.1097/00128488-200109000-00003
Bernigaud, C., Guillemot, D., Ahmed‐Belkacem, A., Grimaldi‐Bensouda, L., Lespine, A., Berry, F., Chosidow, O. (2021). Oral ivermectin for a scabies outbreak in a long‐term care facility: potential value in preventing COVID‐19 and associated mortality. British Journal of Dermatology, 184(6), 1207–1209.
https://doi.org/10.1111/bjd.19821
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021). Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28(4), e434–e460.
https://doi.org/10.1097/mjt.0000000000001402
Caly, Leon, Druce, Julian D., Catton, Mike G., Jans, David A., & Wagstaff, Kylie M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787. doi:
https://doi.org/10.1016/j.antiviral.2020.104787
Chamie-Quintero, J., Hibberd, J., & Scheim, D. (2021). Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in Peru in Close Time Conjunction, State-By-State, with Ivermectin Treatments. SSRN Electronic Journal.
https://doi.org/10.2139/ssrn.3765018
de Melo, G. D., Lazarini, F., Larrous, F., Feige, L., Kornobis, E., Levallois, S., Bourhy, H. (2021). Attenuation of clinical and immunological outcomes during SARS‐CoV‐2 infection by ivermectin. EMBO Molecular Medicine, 13(8).
https://doi.org/10.15252/emmm.202114122
Domingo-Echaburu, Saioa, Orive, Gorka, & Lertxundi, Unax. (2021). Ivermectin & COVID-19: Let’s keep a One Health perspective. Sustainable Chemistry and Pharmacy, 21, 100438. doi:
https://doi.org/10.1016/j.scp.2021.100438
Laing, R., Gillan, V., & Devaney, E. (2017). Ivermectin – Old Drug, New Tricks? Trends in Parasitology, 33(6), 463–472.
https://doi.org/10.1016/j.pt.2017.02.004
Molyneux, D. H., & Ward, S. A. (2015). Reflections on the Nobel Prize for Medicine 2015 – The Public Health Legacy and Impact of Avermectin and Artemisinin. Trends in Parasitology, 31(12), 605–607.
https://doi.org/10.1016/j.pt.2015.10.008
Nemec, J., & Špaček, D. (2020). The Covid-19 pandemic and local government finance: Czechia and Slovakia. Journal of Public Budgeting, Accounting & Financial Management, 32(5), 837–846.
https://doi.org/10.1108/jpbafm-07-2020-0109
World Health Organization, (2021). WHO advises that ivermectin only be used to treat COVID-19 within clinical trials.
Patil, Vaishali, Verma, Saroj, & Masand, Neeraj. (2021). Prospective mode of action of Ivermectin: SARS-CoV-2. European Journal of Medicinal Chemistry Reports, 4, 100018.
https://doi.org/10.1016/j.ejmcr.2021.100018
Rajter, Juliana Cepelowicz, Sherman, Michael S., Fatteh, Naaz, Vogel, Fabio, Sacks, Jamie, & Rajter, Jean-Jacques. (2021). Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest, 159(1), 85-92.
https://doi.org/10.1016/j.chest.2020.10.009
Sohrabi, C., Alsafi, Z., O’Neill, N., Khan, M., Kerwan, A., Al-Jabir, A., Agha, R. (2020). World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery, 76, 71–76.
https://doi.org/10.1016/j.ijsu.2020.02.034
Wagstaff, K., Sivakumaran, H., Heaton, S., Harrich, D., & Jans, D. (2012). Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochemical Journal, 443(3), 851–856.
https://doi.org/10.1042/bj20120150
Yagisawa, Morimasa, Foster, Patrick J, Hanaki, Hideaki, & Ōmura, Satoshi. (2021). Global trends in clinical studies of ivermectin in COVID-19. The japanese journal of antibiotics, 74, 1.
Yamamoto, T., Ozaki, M., Kasugai, D., & Burnham, G. (2021). Assessment of Critical Care Surge Capacity During the COVID-19 Pandemic in Japan. Health Security, 19(5), 479–487.
https://doi.org/10.1089/hs.2020.0227
How to cite this article
Alyasiri, A. J. (2023). Global overview on Treatment COVID-19 in humans with ivermectin. Science Archives, Vol. 4(4), 264-269.
https://doi.org/10.47587/SA.2023.4404
License Article Metadata
This work is licensed under a Creative Commons Attribution 4.0 International License.
